MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.
Stocktwits
MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.
Stocktwits
More News
Coca-Cola Reopens A Costa Sale It Abandoned Earlier This Year, Says Report
Coca-Cola bought Costa Coffee from Whitbread in 2018 for $5.1 billion.
Stocktwits
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year.
Stocktwits
QXO Hits Fresh 52-Week Lows On Soft Residential Roofing Demand
RBC analyst Mike Dahl lowered the firm’s target on QXO to $18 from $27 while maintaining an ‘Outperform’ rating.
Stocktwits
Wall Street Split On Coinbase: Barclays Sees 20% Downside, Goldman Thinks COIN Stock Has Room To Run
Goldman mentioned tight cost control, the SEC's tokenized stock exemption, and a favorable entry point.
Stocktwits
STZ Stock Falls As Modelo And Corona Lose Volume, Full-Year Profit Outlook Holds
Modelo Especial depletions in the quarter were down about 2% and Corona Extra about 5%, partly offset by Pacifico, Victoria, and the Modelo Chelada brands, the company said.
Stocktwits
Lucid Faces A ‘Long And Difficult Journey,’ BNP Says After Q3 Delivery Miss
BNP Paribas analyst said LCID’s “lackluster” delivery report supports his view of a long path to better operations and real demand.
Stocktwits
A Guide to Low-Cost ETFs
Low-cost ETFs can help investors keep more of their returns over time. Here are five ultra-low-cost options spanning U.S. stocks, international markets and bonds.
Zacks
MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns
Nasdaq said on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.
Stocktwits
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.
